Jagdeep S. Sandhu, Ph.D.

Dr. Sandhu obtained his PhD from the University of Cambridge, UK, in 1996. He conducted postgraduate research on transfer of the RSV fusion-protein into plants, at the University of Illinois at Urbana-Champaign (1996-2000, in Buetow-lab), and then as a biotechnologist at the Punjab Agricultural University, India, where he is employed at present.
More Details

Hugh S. Mason, Ph.D.

Dr. Mason was the first to publish peer-reviewed work on the use of plants for production of vaccine antigens, showing expression of authentic hepatitis B surface antigen in tobacco (Mason et al., 1992). He was a leader in this field for many years and continue to publish work in plant-based vaccines (Kim et al., 2015). With funding from NIH-NIAID, Dr. Mason focused on oral delivery of vaccines for enteric diseases including Norwalk virus (Mason et al., 1996) and enterotoxic E. coli (Haq et al., 1995), and demonstrated oral immunogenicity in mice after ingestion of transgenic potato tuber.

More Details

M. Kathleen Buetow, MD, DrPH

Dr. Buetow received an MD from the University of Maryland in 1954 and subsequently did a Pediatric Residency at Baltimore City Hospitals and Cincinnati Children’s Hospital. She then returned to Baltimore to pursue a Doctor of Public Health degree at Johns Hopkins School of Hygiene and Public Health with her thesis work on the topic of Neonatal Mortality. She became a diplomat of the American Academy of Pediatrics (AAP) in 1959, and has been a member of the AAP since then. She is also a member of their sub-committee on Child Abuse and Neglect.

Since 1965, she has been a Pediatric Physician on the staff of Carle Foundation Hospital and a member of the Carle Physician Group in Urbana, Illinois. As a Carle staff member she has also served as Head of the Department of Pediatrics at the University of Illinois College of Medicine at Urbana-Champaign from 1986-2007 and continues on medical school committees as an Emeritus Professor of Clinical Pediatrics. She is also a 20-year member of the University of Illinois Institutional Review Board (IRB). During her years at Carle, Kathleen Buetow has been particularly interested in fostering appropriate immunization practices and serves on Carle’s Immunization Committee. She has a special interest in Child Protection and is involved in many multidisciplinary efforts to prevent, identify and treat instances of child abuse and neglect. She has been involved for the past 20 years on a state Child Death Review Team which seeks to identify and remedy problems associated with Child Mortality.

More Details

Edwin G. Moore, Ph.D.

Dr. Moore brings 30 years of biopharmaceutical, pharmaceutical, and clinical diagnostic industry experience from global companies, Baxter Healthcare Corp and Abbott Laboratories, in R&D product development.  During his career, he has held various roles in CMC pre-clinical product development for recombinant therapeutic proteins and for IV parenteral small molecule products in Analytical Method Development, Stability Testing, Formulation, as well as leading overall pre-clinical product development for a recombinant therapeutic protein product.

In 2014, Ed co-founded BioPhia Consulting, Inc., with three others, and today the company has 15 science and technology subject matter experts in various areas of biopharmaceutical, pharmaceutical, and medical device product development.  Ed also mentors start-up companies at EnterpriseWorks, the University of Illinois incubator.

Ed has PhD degree in Physical Biochemistry from Cornell University, Ithaca, NY, and received BS in Biochemistry from University of Illinois, Champaign-Urbana.

More details

Charles J. Arntzen, Ph.D.

Dr. Arntzen is an elected member of the U.S. National Academy of Sciences and the National Academy of Inventors. He received the USDA Award for Superior Service, and served as chairman of the National Biotechnology Policy Board of the National Institutes of Health. Dr. Arntzen’s primary research interests have been in plant molecular biology and protein engineering, as well as the utilization of plant biotechnology for enhancement of food quality and value, for expression of pharmacologically active products in transgenic plants. He has been recognized as a pioneer in the development of plant-based vaccines for human disease prevention, and for disease prevention in animal agriculture.

Details       More